We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Repeated Application of Gene Therapy in CF Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01621867
Recruitment Status : Completed
First Posted : June 18, 2012
Last Update Posted : October 22, 2015
University of Edinburgh
University of Oxford
Royal Brompton & Harefield NHS Foundation Trust
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
Cystic fibrosis is a genetic condition where epithelial cells, including from the respiratory tract, have an abnormal function of a surface protein, the cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from abnormal gene expression. The trial will assess the clinical efficacy, safety & tolerability and gene expression following repeated nebulised doses of a gene product coding for a normal CFTR protein, with the primary outcome of the trial assessing lung function.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: pGM169/GL67A Drug: Placebo Phase 2

Detailed Description:

Cystic fibrosis (CF), a common, genetically inherited disease, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene encodes the CFTR protein, which is expressed on the apical surface of epithelial cells, and which has many functions, the most important of which is thought to be ion transport. Abnormal ion transport leads to thick secretions in the airways, infection, inflammation and eventually irreversible lung damage. There is currently no treatment that halts the natural progression of the disease; all available successful therapies merely slow the rate of decline in clinical condition.

To date, no viral gene transfer agents retain efficacy upon repeated administration. Our study will assess the safety and efficacy of a lipid-mediated vector harbouring a normal CFTR gene in repeated nebulised administrations. We have completed a single dose safety study which evaluated the safety and gene expression of a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis.

This trial is will randomise 130-patients to receive either a gene product (pGM169/GL67A)encoding for CFTR or placebo in a double-blinded fashion. All subjects will receive 12 doses of nebulised gene therapy at intervals of 4 weeks over a 48 week period. After dose 12 there will be 2 formal follow up visits, at 14 and 28 days post-dose. In addition, patients will be followed up long-term.

Subgroups of patients will be enrolled for gene expression measurement in both nose (at least n=20) and lower airway via bronchoscopy (at least n=20).

The primary outcome of the trial is to evaluate the relative change in predicted Forced Expiratory Volume in 1-second (FEV1) after 12-doses. Secondary outcome measures will assess the efficacy of the gene product (by assessment of patients' physiological function, serological indices, radiological appearances of the lungs and self-reported assessment of quality of life), on the degree of gene expression and on the product safely.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis
Study Start Date : May 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: pGM169/GL67A (CFTR Gene/Lipid Vector) Drug: pGM169/GL67A
5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)

Placebo Comparator: Placebo Drug: Placebo
5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)

Primary Outcome Measures :
  1. Relative change in percent predicted FEV1 after 12 doses of gene product [ Time Frame: 12-months ]

Secondary Outcome Measures :
  1. EFFICACY [ Time Frame: 12-months ]
    Relative change in other spirometric measures; lung clearance index; chest CT scan; Quality of Life Questionnaires; exercise capacity; activity monitoring; serum calprotectin; sputum culture; sputum weight, cell counts and inflammatory markers; frequency of antibiotics for increased chest symptoms

  2. SAFETY [ Time Frame: 12-months ]
    The above efficacy measures; clinical examination; transcutaneous oxygen saturation; serum inflammatory markers (CRP, white blood cell count,cytokines); renal and hepatic function; gas transfer; immune response markers (anti-nuclear and double-stranded DNA antibodies, CFTR-specific T cell responses); endobronchial histology (subgroup only)

  3. GENE EXPRESSION(subgroups only) [ Time Frame: 12-months ]
    Transgene mRNA expression in nasal and lower airway brushing samples; potential difference measurements in nose and bronchi.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Cystic fibrosis confirmed by sweat testing or genetic analysis
  2. Males and females aged 12 years and above
  3. Forced expiratory volume in the 1st second (FEV1) between 50 & 90% predicted inclusive (Stanojevic reference equations).
  4. Clinical stability at screening defined by:

    1. Not on any additional antibiotics (excluding routine, long-term treatments) for the previous 2 weeks
    2. No increase in symptoms such as change in sputum production/colour, increased wheeze or breathlessness over the previous 2 weeks
    3. No change in regular respiratory treatments over the previous 4 weeks
    4. If any of these apply, entry into the study can be deferred
  5. Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter (as stated in GTAC guidelines)
  6. If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose (nebulised doses only)
  7. Written informed consent obtained
  8. Permission to inform their general practitioner of participation in study

Exclusion Criteria:

  1. Infection with Burkholderia cepacia complex organisms, MRSA or M. abscessus
  2. Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds) (nasal cohort only)
  3. Chloride secretory response on nasal PD of > 5 mV (nasal cohort only; will only be known after first measurement)
  4. Acute upper respiratory tract infection within the last 2 weeks (entry can be deferred)
  5. Previous spontaneous pneumothorax without pleurodesis (bronchoscopic subgroup only)
  6. Recurrent severe haemoptysis (bronchoscopic subgroup only)
  7. Current smoker
  8. Significant comorbidity including:

    1. Moderate/severe CF liver disease (varices or significant, sustained elevation of transaminases: ALT/ AST>100 IU/l)
    2. Significant renal impairment (serum creatinine > 150 mmol/l)
    3. Significant coagulopathy (bronchoscopic group only)
  9. Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations
  10. Pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01621867

Layout table for location information
United Kingdom
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Royal Hospital for Sick Children
Edinburgh, United Kingdom, EH9 1LF
Royal Brompton Hospital
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Imperial College London
University of Edinburgh
University of Oxford
Royal Brompton & Harefield NHS Foundation Trust
Layout table for investigator information
Study Director: Eric Alton, MD, FMedSci Imperial College London
Principal Investigator: Jane Davies, MD Imperial College London
Principal Investigator: Uta Griesenbach, PhD Imperial College London
Principal Investigator: Steve Hyde, MA, DPhil University of Oxford
Principal Investigator: Deborah Gill, PhD University of Oxford
Principal Investigator: Chris Boyd, PhD Edinburgh University
Principal Investigator: David Porteous, FMedSci Edinburgh University
Principal Investigator: Alastair Innes, PhD Edinburgh University
Principal Investigator: Steve Cunningham, PhD Edinburgh University
Additional Information:
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01621867    
Other Study ID Numbers: ICL/CRO-1881
2011-004761-33 ( EudraCT Number )
First Posted: June 18, 2012    Key Record Dates
Last Update Posted: October 22, 2015
Last Verified: November 2012
Keywords provided by Imperial College London:
Cystic fibrosis
Gene therapy
CFTR gene
Gene expression
Multi dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases